

# William Busse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8421906/publications.pdf>

Version: 2024-02-01

256  
papers

35,875  
citations

4641

85  
h-index

3257

185  
g-index

261  
all docs

261  
docs citations

261  
times ranked

18308  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 315-323.	2.5	1,820
2	Asthma. New England Journal of Medicine, 2001, 344, 350-362.	13.9	1,683
3	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	2.5	1,591
4	Can Guideline-defined Asthma Control Be Achieved?. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 836-844.	2.5	1,489
5	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. New England Journal of Medicine, 2018, 378, 2486-2496.	13.9	1,253
6	Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Journal of Allergy and Clinical Immunology, 2001, 108, 184-190.	1.5	1,147
7	Benralizumab, an anti-interleukin-5 receptor $\hat{\pm}$ monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2016, 388, 2128-2141.	6.3	1,070
8	Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Journal of Allergy and Clinical Immunology, 2007, 119, 405-413.	1.5	838
9	Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. New England Journal of Medicine, 2011, 364, 1005-1015.	13.9	783
10	Exploring the Effects of Omalizumab in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 804-811.	2.5	772
11	Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet, The, 2003, 361, 1071-1076.	6.3	705
12	A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1062-1071.	2.5	672
13	Role of viral respiratory infections in asthma and asthma exacerbations. Lancet, The, 2010, 376, 826-834.	6.3	624
14	Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 583-593.	2.5	588
15	Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1294-1302.	2.5	532
16	Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. Journal of Allergy and Clinical Immunology, 2014, 133, 1557-1563.e5.	1.5	488
17	Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy. Annals of Internal Medicine, 2011, 154, 573.	2.0	460
18	Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. Journal of Allergy and Clinical Immunology, 2020, 146, 203-206.e3.	1.5	453

#	ARTICLE	IF	CITATIONS
19	Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1476-1485.	1.5	452
20	Benralizumab, an anti-interleukin 5 receptor $\hat{\pm}$ monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 879-890.	5.2	435
21	Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1086-1096.e5.	1.5	422
22	Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. <i>Lancet</i> , 2008, 372, 1065-1072.	6.3	414
23	Severe Exacerbations and Decline in Lung Function in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 19-24.	2.5	377
24	Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 593-601.e12.	1.5	333
25	Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 134-140.	1.5	329
26	Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 1997, 100, 110-121.	1.5	326
27	Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1294-1302.	2.5	318
28	Type 2 immunity in the skin and lungs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1582-1605.	2.7	304
29	Immediate and Late Airway Response of Allergic Rhinitis Patients to Segmental Antigen Challenge: Characterization of Eosinophil and Mast Cell Mediators. <i>The American Review of Respiratory Disease</i> , 1991, 144, 1274-1281.	2.9	291
30	Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 918-927.	2.0	283
31	A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4R $\hat{\pm}$ Antagonist, in Patients with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 788-796.	2.5	282
32	The role of viral infections in the natural history of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, 201-212.	1.5	281
33	Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. <i>Journal of Applied Physiology</i> , 2008, 104, 394-403.	1.2	270
34	Asthma: Clinical expression and molecular mechanisms. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, S95-S102.	1.5	268
35	Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor $\hat{\pm}$ antibody, in a phase I study of subjects with mild asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1237-1244.e2.	1.5	260
36	School Examinations Enhance Airway Inflammation to Antigen Challenge. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1062-1067.	2.5	258

#	ARTICLE	IF	CITATIONS
37	Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, at-Risk Phenotype among Patients with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1033-1041.	2.5	252
38	Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1280-1288.	1.5	247
39	Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 356-362.	2.5	242
40	Ragweed Immunotherapy in Adult Asthma. <i>New England Journal of Medicine</i> , 1996, 334, 501-507.	13.9	223
41	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 46-59.	5.2	216
42	Severe asthma: Lessons from the Severe Asthma Research Program. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 14-21.	1.5	209
43	Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 985-992.	2.5	200
44	Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 383-389.	1.5	199
45	Quantitative and Qualitative Analysis of Rhinovirus Infection in Bronchial Tissues. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 645-651.	2.5	197
46	From The Cover: Neural circuitry underlying the interaction between emotion and asthma symptom exacerbation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 13319-13324.	3.3	192
47	DNA methylation and childhood asthma in the inner city. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 69-80.	1.5	189
48	Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, 457-463.	1.5	179
49	Omaliuzumab in Asthma: An Update on Recent Developments. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 525-536.e1.	2.0	179
50	Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 190-200.e20.	1.5	175
51	Omaliuzumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 156-164.e1.	2.0	173
52	Decreased Expression of Membrane IL-5 Receptor $\alpha$ on Human Eosinophils: I. Loss of Membrane IL-5 Receptor $\alpha$ on Airway Eosinophils and Increased Soluble IL-5 Receptor $\alpha$ in the Airway After Allergen Challenge. <i>Journal of Immunology</i> , 2002, 169, 6452-6458.	0.4	169
53	A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 162-169.e2.	1.5	162
54	Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. <i>Lancet</i> , 2017, 389, 157-166.	6.3	158

#	ARTICLE	IF	CITATIONS
55	Age-Related Changes in Eosinophil Function in Human Subjects. <i>Chest</i> , 2008, 133, 412-419.	0.4	147
56	The Relationship of Airway Hyperresponsiveness and Airway Inflammation. <i>Chest</i> , 2010, 138, 4S-10S.	0.4	144
57	An expert consensus framework for asthma remission as a treatment goal. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 757-765.	1.5	144
58	Omalizumab and the risk of malignancy: Results from a pooled analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 983-989.e6.	1.5	143
59	Seasonal risk factors for asthma exacerbations among inner-city children. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1465-1473.e5.	1.5	143
60	Cysteinyl Leukotrienes in Allergic Inflammation*. <i>Chest</i> , 2005, 127, 1312.	0.4	141
61	Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1735-1743.e9.	1.5	139
62	Daclizumab Improves Asthma Control in Patients with Moderate to Severe Persistent Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1002-1008.	2.5	137
63	High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 485-486.e11.	1.5	134
64	The nasal methylome and childhood atopic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1478-1488.	1.5	133
65	Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1431-1444.	1.5	130
66	Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1449-1463.	2.5	130
67	Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. <i>Advances in Therapy</i> , 2018, 35, 737-748.	1.3	129
68	The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: Effectiveness of early intervention with budesonide in mild persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 1167-1174.	1.5	126
69	Relationship of viral infections to wheezing illnesses and asthma. <i>Nature Reviews Immunology</i> , 2002, 2, 132-138.	10.6	124
70	Biological treatments for severe asthma: A major advance in asthma care. <i>Allergology International</i> , 2019, 68, 158-166.	1.4	122
71	The effect of an experimental rhinovirus 16 infection on bronchial lavage neutrophils. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 1169-1177.	1.5	120
72	Asthma phenotypes in inner-city children. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1016-1029.	1.5	120

#	ARTICLE	IF	CITATIONS
73	Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 692-698.	1.5	118
74	Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 30-37.e6.	1.5	114
75	Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 694-701.	1.5	114
76	The Presence of Rhinovirus in Lower Airways of Patients with Bronchial Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1082-1089.	2.5	112
77	Generation of Th1 and Th2 Chemokines by Human Eosinophils: Evidence for a Critical Role of TNF- $\alpha$ . <i>Journal of Immunology</i> , 2007, 179, 4840-4848.	0.4	110
78	Rhinovirus-induced Interferon- $\beta$ and Airway Responsiveness in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 1091-1094.	2.5	106
79	Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children. <i>Nature Immunology</i> , 2019, 20, 637-651.	7.0	106
80	Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting $\beta_2$ agonist treatment in a multiethnic asthma population: a genetic study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 204-213.	5.2	100
81	Host immune responses to rhinovirus: Mechanisms in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 671-682.	1.5	96
82	Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1030-1041.	1.5	92
83	Histamine inhibition of neutrophil lysosomal enzyme release: an H2 histamine receptor response. <i>Science</i> , 1976, 194, 737-738.	6.0	90
84	The Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods, and study population. <i>BMC Pulmonary Medicine</i> , 2009, 9, 17.	0.8	90
85	Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma. <i>Chest</i> , 2013, 144, 1222-1229.	0.4	86
86	Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 245-252.e3.	1.5	83
87	A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 803-813.	1.5	83
88	Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 339-345.	1.5	82
89	Addressing issues of asthma in inner-city children. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 43-49.	1.5	81
90	The Poorly Explored Impact of Uncontrolled Asthma. <i>Chest</i> , 2013, 143, 511-523.	0.4	81

#	ARTICLE	IF	CITATIONS
91	Steroid-sparing effects of fluticasone propionate 100 $\hat{1}$ / <sub>4</sub> g and salmeterol 50 $\hat{1}$ / <sub>4</sub> g administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 $\hat{1}$ / <sub>4</sub> g administered twice daily. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 57-65.	1.5	79
92	Biomarkers in asthmatic patients: Has their time come to direct treatment?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1317-1324.	1.5	79
93	Care pathways for the selection of a biologic in severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1701782.	3.1	79
94	Characteristics of Perimenstrual Asthma and Its Relation to Asthma Severity and Control. <i>Chest</i> , 2013, 143, 984-992.	0.4	78
95	Combined Analysis of Asthma Safety Trials of Long-Acting $\hat{1}^2$ -Agonists. <i>New England Journal of Medicine</i> , 2018, 378, 2497-2505.	13.9	76
96	Childhood- versus adult-onset asthma.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1635-1639.	2.5	75
97	Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. <i>Thorax</i> , 2014, 69, 312-319.	2.7	73
98	The effect of azelastine on neutrophil and eosinophil generation of superoxide. <i>Journal of Allergy and Clinical Immunology</i> , 1989, 83, 400-405.	1.5	72
99	Results of the First U.S. Double-Blind, Placebo-Controlled, Multicenter Clinical Study in Asthma with Pranlukast, a Novel Leukotriene Receptor Antagonist. <i>Journal of Asthma</i> , 1997, 34, 321-328.	0.9	72
100	Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. <i>Thorax</i> , 2012, 67, 35-41.	2.7	72
101	Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. <i>European Respiratory Journal</i> , 2014, 43, 773-782.	3.1	72
102	Are There Neurophenotypes for Asthma? Functional Brain Imaging of the Interaction between Emotion and Inflammation in Asthma. <i>PLoS ONE</i> , 2012, 7, e40921.	1.1	71
103	Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1165-1173.	5.2	70
104	Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the $\hat{1}^2$ -agonist vilanterol administered once daily for 52 weeks in patients $\hat{1}^2$ -years old with asthma: a randomised trial. <i>Thorax</i> , 2013, 68, 513-520.	2.7	69
105	Biologics in Asthmaâ€”The Next Step Toward Personalized Treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 152-160.	2.0	69
106	Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. <i>European Respiratory Journal</i> , 2021, 58, 2003393.	3.1	69
107	The Relationship of Rhinovirusâ€”Associated Asthma Hospitalizations with Inhaled Corticosteroids and Smoking. <i>Journal of Infectious Diseases</i> , 2006, 193, 1536-1543.	1.9	68
108	Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial. <i>Respiratory Medicine</i> , 2012, 106, 642-650.	1.3	67

#	ARTICLE	IF	CITATIONS
109	24-h duration of the novel LABA vilanterol trifenate in asthma patients treated with inhaled corticosteroids. <i>European Respiratory Journal</i> , 2012, 40, 570-579.	3.1	65
110	House dust mite sublingual immunotherapy: Results of a US trial. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 974-981.e7.	1.5	64
111	Pathways through which asthma risk factors contribute to asthma severity in inner-city children. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1042-1050.	1.5	64
112	Future Research Directions in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 683-690.	2.5	63
113	Predicting Intermediate Phenotypes in Asthma Using Bronchoalveolar Lavage-Derived Cytokines. <i>Clinical and Translational Science</i> , 2010, 3, 147-157.	1.5	62
114	Determinants of Exhaled Breath Condensate pH in a Large Population With Asthma. <i>Chest</i> , 2011, 139, 328-336.	0.4	61
115	Reassessment of Omalizumab-Dosing Strategies and Pharmacodynamics in Inner-City Children and Adolescents. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 163-171.	2.0	60
116	Mind-body interactions in the regulation of airway inflammation in asthma: A PET study of acute and chronic stress. <i>Brain, Behavior, and Immunity</i> , 2016, 58, 18-30.	2.0	59
117	Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, S1-S14.	2.0	57
118	Up-Regulation and Activation of Eosinophil Integrins in Blood and Airway after Segmental Lung Antigen Challenge. <i>Journal of Immunology</i> , 2008, 180, 7622-7635.	0.4	55
119	Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1003-1011.e10.	1.5	55
120	Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. <i>Current Medical Research and Opinion</i> , 2007, 23, 2379-2386.	0.9	53
121	Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. <i>European Respiratory Journal</i> , 2019, 53, 1800948.	3.1	49
122	Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma. <i>PLoS ONE</i> , 2015, 10, e0145476.	1.1	49
123	Development of cockroach immunotherapy by the Inner-City Asthma Consortium. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 846-852.e6.	1.5	48
124	Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 109, 353-358.e4.	0.5	47
125	Expression quantitative trait locus fine mapping of the 17q12 asthma locus in African American children: a genetic association and gene expression study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 482-492.	5.2	47
126	Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 527-539.e9.	2.0	45



#	ARTICLE	IF	CITATIONS
127	Asthma diagnosis and treatment: Filling in the information gaps. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 740-750.	1.5	42
128	Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. <i>Respiratory Research</i> , 2011, 12, 160.	1.4	42
129	Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 1407-1414.e6.	1.5	41
130	Allergen Immunotherapy in Allergic Respiratory Diseases. <i>Chest</i> , 2012, 141, 1303-1314.	0.4	41
131	Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1130-1137.e5.	1.5	41
132	Longitudinal Changes in Airway Remodeling and Air Trapping in Severe Asthma. <i>Academic Radiology</i> , 2014, 21, 986-993.	1.3	40
133	Fluticasone Furoate + Vilanterol 100-25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 553-561.	2.0	40
134	Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 565-576.e1.	0.5	40
135	Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 190-196.	0.5	39
136	Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 430-433.	1.5	38
137	Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 96, 60-68.	0.5	37
138	Severe Asthma: An Expanding and Mounting Clinical Challenge. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 110-121.	2.0	37
139	Efficacy and safety of fluticasone furoate 100/4g once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. <i>Respiratory Medicine</i> , 2014, 108, 41-49.	1.3	37
140	BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 837-856.	2.5	37
141	Obstruction phenotype as a predictor of asthma severity and instability in children. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1090-1099.e4.	1.5	36
142	Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 130-137.e3.	1.5	35
143	How cytokines co-occur across asthma patients: From bipartite network analysis to a molecular-based classification. <i>Journal of Biomedical Informatics</i> , 2011, 44, S24-S30.	2.5	35
144	Roflumilast for asthma: Efficacy findings in placebo-controlled studies. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 35, S20-S27.	1.1	35

#	ARTICLE	IF	CITATIONS
145	Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. <i>Journal of Family Practice</i> , 2001, 50, 595-602.	0.2	35
146	Serum IL-6: A biomarker in childhood asthma?. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1701-1704.e3.	1.5	34
147	New directions and dimensions in the treatment of allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 1988, 82, 890-900.	1.5	33
148	The National Institutes of Allergy and Infectious Diseases networks on asthma in inner-city children: An approach to improved care. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 529-537.	1.5	33
149	The Relationship of Asthma Biologics to Remission for Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1090-1098.	2.0	33
150	The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study. <i>Contemporary Clinical Trials</i> , 2001, 22, 405-419.	2.0	32
151	Safety and tolerability of once-daily tiotropium Respimat Â® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. <i>Respiratory Medicine</i> , 2016, 118, 102-111.	1.3	31
152	The atopic march: Fact or folklore?. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 116-118.	0.5	31
153	Seasonal airway microbiome and transcriptome interactions promote childhood asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 204-213.	1.5	31
154	Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?. <i>European Respiratory Review</i> , 2016, 25, 54-64.	3.0	30
155	Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. <i>Journal of Asthma</i> , 2021, 58, 514-522.	0.9	30
156	Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: Role of predictors in the setting of high adherence. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 213-221.e1.	1.5	28
157	<p>Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma</p>. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 401-413.	1.5	28
158	<i>In Vitro</i> Incubation with Influenza Virus Primes Human Polymorphonuclear Leukocyte Generation of Superoxide. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1991, 4, 347-354.	1.4	27
159	Characterization of factors associated with systemic corticosteroid use in severe asthma: Data from the Severe Asthma Research Program. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 915-918.	1.5	27
160	Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 524-532.e2.	0.5	27
161	<i>HSD3B1</i> genotype identifies glucocorticoid responsiveness in severe asthma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2187-2193.	3.3	27
162	What is the contribution of IgE to nasal polyposis?. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1997-2008.	1.5	27

#	ARTICLE	IF	CITATIONS
163	Discriminating sputum-eosinophilic asthma: Accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 812-814.e2.	1.5	26
164	Phenotype of asthmatics with increased airway <i>S</i> -nitrosoglutathione reductase activity. <i>European Respiratory Journal</i> , 2015, 45, 87-97.	3.1	26
165	Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1856-1866.	1.5	26
166	Benefits of Airway Androgen Receptor Expression in Human Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 285-293.	2.5	26
167	A role for neutrophils in asthma exacerbations. <i>Nature Medicine</i> , 2017, 23, 658-659.	15.2	24
168	Neuroimaging and biomarker evidence of neurodegeneration in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 589-598.e6.	1.5	24
169	The Role of Respiratory Viruses in Asthma. <i>Novartis Foundation Symposium</i> , 1997, 206, 208-219.	1.2	24
170	Current unmet needs and potential solutions to uncontrolled asthma. <i>European Respiratory Review</i> , 2022, 31, 210176.	3.0	24
171	Expression of asthma susceptibility genes in bronchial epithelial cells and bronchial alveolar lavage in the Severe Asthma Research Program (SARP) cohort. <i>Journal of Asthma</i> , 2016, 53, 775-782.	0.9	23
172	Reducing Exacerbations in the Inner City: Lessons from the Inner-City Asthma Consortium (ICAC). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 22-26.	2.0	23
173	New and Anticipated Therapies for Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, S15-S24.	2.0	23
174	Biological treatments for severe asthma: where do we stand?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 509-518.	1.1	23
175	Efficacy and safety of fluticasone furoate 100 $\hat{A}$ ¼g and 200 $\hat{A}$ ¼g once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 113.	0.8	22
176	Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 266-271.e2.	1.5	22
177	Tiotropium add-on to inhaled corticosteroids versus addition of long-acting $\hat{A}$ 2-agonists for adults with asthma. <i>Respiratory Medicine</i> , 2018, 143, 82-90.	1.3	21
178	The Brain and Asthma: What Are the Linkages?. <i>Chemical Immunology and Allergy</i> , 2012, 98, 14-31.	1.7	20
179	Asthma: Diagnosis and Management. <i>Medical Clinics of North America</i> , 2006, 90, 39-60.	1.1	19
180	Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. <i>Respiratory Research</i> , 2014, 15, 88.	1.4	19

#	ARTICLE	IF	CITATIONS
181	Designing clinical trials to address the needs of childhood and adult asthma: The National Heart, Lung, and Blood Institute's AsthmaNet. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 34-38.e1.	1.5	19
182	Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 767-773.e6.	1.5	19
183	Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. <i>Clinical Therapeutics</i> . 2004, 26, 1587-1598.	1.1	18
184	What Is the Best Pulmonary Diagnostic Approach for Wheezing Patients With Normal Spirometry?. <i>Respiratory Care</i> , 2012, 57, 39-49.	0.8	18
185	Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. <i>Journal of Negative Results in BioMedicine</i> , 2014, 13, 9.	1.4	18
186	Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. <i>BMC Pulmonary Medicine</i> , 2016, 16, 65.	0.8	18
187	IgE-mediated asthma: New revelations and future insights. <i>Respiratory Medicine</i> , 2016, 112, 128-129.	1.3	18
188	Treatment Regimen and Side Effects of Treatment Measures. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1994, 149, S44-S50.	2.5	17
189	Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 732-741.	2.0	16
190	Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 35, S28-S34.	1.1	15
191	Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2673-2680.e3.	2.0	15
192	Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3021-3028.e2.	2.0	15
193	Holy Grail: the journey towards disease modification in asthma. <i>European Respiratory Review</i> , 2022, 31, 210183.	3.0	15
194	Corticosteroids in the Treatment of Asthma. <i>BioDrugs</i> , 1995, 4, 16-48.	0.7	14
195	Asthma and infections: Is the risk more profound than previously thought?. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 260-261.	1.5	14
196	Inducible expression quantitative trait locus analysis of the MUC5AC gene in asthma in urban populations of children. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1505-1514.	1.5	14
197	Effect of Bordetella pertussis Vaccination in Mice and the Isolated Tracheal Response to Isoprenaline. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1980, 35, 291-296.	2.7	13
198	Is the Eosinophil a "Humpty Dumpty" Cell in Asthma?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 102-103.	2.5	13

#	ARTICLE	IF	CITATIONS
199	Biologic Therapy and Asthma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 100-114.	0.8	13
200	A computerized decision support tool to implement asthma guidelines for children and adolescents. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1760-1768.	1.5	13
201	Uncontrolled asthma across GINA treatment steps 2â€™%â€™â€™5 in a large US patient cohort. <i>Journal of Asthma</i> , 2022, 59, 1051-1062.	0.9	13
202	Prevention and Treatment of Asthma Exacerbations in Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2578-2586.	2.0	13
203	The role of allergy in disease. <i>Immunological Reviews</i> , 2011, 242, 5-9.	2.8	12
204	How to compare the efficacy of biologic agents in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 137-149.	0.5	12
205	Anti-immunoglobulin E for the treatment of allergic disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 105-108.	1.1	11
206	Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma*1. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, S286-S287.	1.5	11
207	Biologic therapies for asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 19-24.	1.2	11
208	Dust Miteâ€™Induced Perennial Allergic Rhinitis in Pediatric Patients and Sublingual Immunotherapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 46-51.	2.0	10
209	Global Initiative for Asthma 2016â€™derived asthma control with fluticasone propionate and salmeterol. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 57-63.e2.	0.5	10
210	Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. <i>European Respiratory Journal</i> , 2021, 58, 2004605.	3.1	10
211	Executive Summary: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. <i>Annals of the American Thoracic Society</i> , 2014, 11, S123-S124.	1.5	9
212	Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. <i>Respiratory Research</i> , 2016, 17, 157.	1.4	9
213	A Deep Dive into Asthma Transcriptomics. Lessons from U-BIOPRED. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1279-1280.	2.5	9
214	Controversies and opportunities in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 83-93.	1.2	9
215	Expression of corticosteroid-regulated genes by PBMCs in children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 940-947.e6.	1.5	8
216	Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1201-1211.	2.0	8

#	ARTICLE	IF	CITATIONS
217	Anaphylaxis Conundrum: A Trojan Horse Phenomenon. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 325-329.	2.0	7
218	Asthma and psoriasis: What do they have in common? IL-17A!. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1169-1171.	1.5	7
219	Association of mold levels in urban children's homes with difficult-to-control asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1481-1485.	1.5	7
220	Effect of Nedocromil Sodium on the $\beta_2$ -Adrenergic Response of Human Polymorphonuclear Leucocytes <sup>1</sup> . <i>Drugs</i> , 1989, 37, 26-31.	4.9	6
221	Is It Asthma or Is It COPD: The Overlap Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 641-642.	2.0	6
222	Treatable traits: a step closer to the "holy grail" of asthma control?. <i>European Respiratory Journal</i> , 2020, 55, 2000002.	3.1	6
223	Does IgE Have a Role in Aspirin-exacerbated Respiratory Disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1459-1460.	2.5	6
224	Insights from the AUSTRI study on reliever use before and after asthma exacerbations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1916-1918.e2.	2.0	6
225	Biologics for asthma in patients with asthma-COPD overlap. <i>Lancet Respiratory Medicine</i> , 2017, 5, 175-177.	5.2	5
226	Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!. <i>European Respiratory Journal</i> , 2018, 51, 1800730.	3.1	5
227	Determinants of Risk Factors for Asthma. <i>Canadian Respiratory Journal</i> , 1999, 6, 97-101.	0.8	4
228	Cockroach-induced IL9, IL13, and IL31 expression and the development of allergic asthma in urban children. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1974-1977.e3.	1.5	4
229	Weaving innate lymphoid cells (ILCs) into the fabric of asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1579-1581.	1.5	4
230	Anti-immunoglobulin E for the treatment of allergic disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 105-108.	1.1	4
231	Cysteinyl Leukotrienes in Allergic Inflammation. <i>Chest</i> , 2005, 127, 1312-1326.	0.4	3
232	What Are Those Neutrophils Doing in Severe Asthma Anyway?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 526-528.	2.0	3
233	Biologic Therapy in Allergy Practice: A New Era in Treatment Has Begun. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1118-1120.	2.0	3
234	School Classrooms as Targets to Reduce Allergens and Improve Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 816.	3.8	3

#	ARTICLE	IF	CITATIONS
235	Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study. <i>BMC Pulmonary Medicine</i> , 2017, 17, 75.	0.8	2
236	How Sex and Age of Asthma Onset Influence Difficult Asthma Heterogeneity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3407-3408.	2.0	2
237	Development of nasal allergen challenge with cockroach in children with asthma. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 971-979.	1.1	2
238	Mentoring: A lifetime cycle and key to successful career development. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1634-1637.	1.5	2
239	Combination Low-Dose Metaproterenol-Theophylline Therapy in Asthma. <i>Journal of Asthma</i> , 1983, 20, 85-91.	0.9	1
240	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Efficacy and Tolerability of Levocabastine-Oxymetazoline Nasal Spray with Levocabastine and Oxymetazoline Alone in the Symptomatic Treatment of Seasonal Allergic Rhinitis. <i>American Journal of Rhinology &amp; Allergy</i> , 1996, 10, 105-112.	2.3	1
241	An Integrated Analysis of Fluticasone Furoate/Vilanterol (FF/VI) Versus FF Safety Data Across Phase II and III Asthma Studies. <i>Pulmonary Therapy</i> , 2016, 2, 91-114.	1.1	1
242	Are Biotherapeutics Revolutionizing Treatment of Allergic Diseases?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1517-1518.	2.0	1
243	In lasting tribute: Charles E. Reed, March 13, 1922, to July 24, 2020. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 984-986.	1.5	1
244	Asthma and pregnancy: do they give clues to abnormal antiviral activity?. <i>Thorax</i> , 2012, 67, 189-190.	2.7	0
245	Authors' reply to "Safety and tolerability of fluticasone furoate/vilanterol". <i>Thorax</i> , 2013, 68, 1165.2-1166.	2.7	0
246	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1231.	1.5	0
247	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1408-1409.	1.5	0
248	Safety Trials of Long-Acting $\beta_2$ -Agonists. <i>New England Journal of Medicine</i> , 2018, 379, 1481-1482.	13.9	0
249	"Knowing When to Hold'em and When to Fold'em" with Biological Treatments of Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 883-885.	2.0	0
250	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1267-1268.	1.5	0
251	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1214-1215.	1.5	0
252	The "Asthma Guidelines": What Do the Experts Teach Us?. , 2008, , 165-176.		0

#	ARTICLE	IF	CITATIONS
253	Management of Asthma in Adolescents and Adults. , 2014, , 902-922.		0
254	Bronchodilator Responsiveness: An Underappreciated Biomarker for Asthma Exacerbations. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 229-230.	2.0	0
255	Perspectives in Respiratory Infections and the Lung. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 694-696.	2.0	0
256	Relation Between Fractional Exhaled Nitric Oxide Reductions and Efficacy Outcomes in Patients with Asthma Treated with Dupilumab. , 2022, , .		0